<DOC>
	<DOCNO>NCT02736578</DOCNO>
	<brief_summary>This phase I/II trial study side effect best dose cetuximab-IRDye 800CW use intraoperative imaging see well work find pancreatic cancer patient undergo surgery . Cetuximab-IRDye 800CW may help doctor good identify cancer operate room make cancer visible view special imaging device .</brief_summary>
	<brief_title>Cetuximab-IRDye 800CW Intraoperative Imaging Finding Pancreatic Cancer Patients Undergoing Surgery</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . To determine efficacy cetuximab IRDye800 ( cetuximab-IRDye 800CW ) intraoperatively identify pancreatic cancer compare surround normal pancreatic extrapancreatic tissue , measure tumor-to-background ratio . SECONDARY OBJECTIVES : I . To determine tolerability cetuximab IRDye800 imaging agent patient undergoing resection pancreatic cancer . OUTLINE : This dose-escalation study . Patients receive cetuximab-IRDye 800CW intravenously ( IV ) 30 minute 1 hour day 0 . Within 2-5 day , patient undergo surgery intraoperative imaging . After completion study treatment , patient follow day 10 30 .</detailed_description>
	<mesh_term>Adenocarcinoma</mesh_term>
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<mesh_term>Cetuximab</mesh_term>
	<criteria>Clinically suspect biopsy confirm diagnosis pancreatic adenocarcinoma Planned standard care surgery curative intent pancreatic adenocarcinoma Life expectancy 12 week Karnofsky performance status least 70 % Eastern Cooperative Oncology Group ( ECOG ) /Zubrod level 1 Hemoglobin &gt; = 9 gm/dL Platelet count &gt; = 100,000/mm^3 Magnesium , potassium calcium &gt; low limit normal per institution normal lab value Thyroidstimulating hormone ( TSH ) &lt; 13 micro International units/mL Received investigational drug within 30 day prior first dose cetuximab IRDye800 Myocardial infarction ( MI ) ; cerebrovascular accident ( CVA ) ; uncontrolled congestive heart failure ( CHF ) ; unstable angina within 6 month prior enrollment History infusion reaction cetuximab monoclonal antibody therapy Pregnant breastfeed Patients serious reaction test/loading cetuximab dose able receive full dose Evidence QT prolongation pretreatment electrocardiography ( ECG ) ( great 440 m male great 450 m female ) Lab value opinion primary surgeon would prevent surgical resection Patients receive class IA ( quinidine , procainamide ) class III ( dofetilide , amiodarone , sotalol ) antiarrhythmic agent</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>